Thermo Fisher Scientific Inc. TMO financials

Healthcare & Pharma · Statements and segments from its SEC filings, 2007 to 2025.

Thermo Fisher Scientific Inc. revenue, gross and operating margin, net income, free cash flow, cash and debt by quarter and by fiscal year, and revenue by segment, read from the company's own filings with the US Securities and Exchange Commission. Free to everyone; the Risk & Quality report that scores the company is the paid step.

revenue by segment: Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Research and safety market channel, Genetic sciences, Laboratory products, Healthcare market channel, Transplant diagnostics
revenue by product: Consumables, Service revenues, Instruments, Product revenues
revenue by region: North America, Europe, Asia-Pacific, Other regions, United States, Other, China
operating income by segment: Life Sciences Solutions, Laboratory Products and Biopharma Services, Analytical Instruments, Specialty Diagnostics

The numbers

Annual figures

Line	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$18.3B	$20.9B	$24.4B	$25.5B	$32.2B	$39.2B	$44.9B	$42.9B	$42.9B	$44.6B
Gross profit	$10.1B*	$11.9B*	-	-	-	-	-	-	-	-
Operating income	$2.5B	$3B	$3.8B	$4.6B	$7.8B	$10B	$8.4B	$6.9B	$7.3B	$7.7B
Net income	$2B	$2.2B	$2.9B	$3.7B	$6.4B	$7.7B	$7B	$6B	$6.3B	$6.7B
EPS (diluted)	$5.09	$5.59	$7.24	$9.17	$15.96	$19.46	$17.63	$15.45	$16.53	$17.74
Operating cash flow	$3.3B	$4B	$4.5B	$5B	$8.3B	$9.3B	$9.2B	$8.4B	$8.7B	$7.8B
Free cash flow	$2.8B*	$3.5B*	$3.8B*	$4B*	$6.8B*	$6.8B*	$6.9B*	$6.9B*	$7.3B*	$6.3B*
Cash & equivalents	$786M	$1.3B	$2.1B	$2.4B	$10.3B	$4.5B	$8.5B	$8.1B	$4B	$9.9B
Total debt	$15.4B	$18.9B	$19B	$17.8B	$21.7B	$34.7B	$34.3B	$34.7B	$31.1B	$39.2B
Gross margin	55.1%	57.1%	-	-	-	-	-	-	-	-
Operating margin	13.5%	14.2%	15.5%	18.0%	24.2%	25.6%	18.7%	16.0%	17.1%	17.4%
Net margin	11.1%	10.6%	12.1%	14.5%	19.8%	19.7%	15.5%	14.0%	14.8%	15.0%

Latest quarters

Line	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$10.6B	$11.4B*	$10.4B	$10.9B	$11.1B	$12.2B*	$11B	$12B
Operating income	$1.8B	$2B*	$1.7B	$1.8B	$1.9B	$2.3B*	$1.9B	$2.1B
Net income	$1.6B	$1.8B*	$1.5B	$1.6B	$1.6B	$2B*	$1.7B	$1.7B
EPS (diluted)	$4.25	$4.78*	$3.98	$4.28	$4.27	$5.21*	$4.43	$4.68
Operating cash flow	$2.2B*	$3.3B*	$723M	$1.4B*	$2.2B*	$3.5B*	$1.2B	$2.1B*
Free cash flow	$1.9B*	$2.8B*	$361M*	$1.1B*	$1.8B*	$3B*	$816M*	$1.7B*
Cash & equivalents	$4.6B	$4B	$4.1B	$4.6B	$2B	$9.9B	$3.3B	$4.1B
Total debt	$35.1B	$31.1B	$34B	$35B	$35.5B	$39.2B	$42.9B	$42.3B
Operating margin	17.3%	17.7%	16.6%	16.9%	17.5%	18.5%	16.9%	17.4%
Net margin	15.4%	16.1%	14.5%	14.9%	14.5%	16.1%	15.0%	14.5%

Revenue by segment

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Laboratory Products and Biopharma Services	$7.8B	$10B	$10.6B	$12.2B	$14.9B	$22.5B	$23B	$23.2B	$24B
Life Sciences Solutions	$5.7B	$6.3B	$6.9B	$12.2B	$15.6B	$13.5B	$10B	$9.6B	$10.4B
Analytical Instruments	$4.8B	$5.5B	$5.5B	$5.1B	$6.1B	$6.6B	$7.3B	$7.5B	$7.6B
Specialty Diagnostics	$3.5B	$3.7B	$3.7B	$5.3B	$5.7B	$4.8B	$4.4B	$4.5B	$4.7B

Segment figures include sales between segments, so they add up to more than consolidated revenue.

Revenue by product

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Consumables	-	$12.6B	$13.1B	$18.5B	$22.6B	$20.6B	$17.6B	$17.6B	$18.7B
Service revenues	$3.5B	$5.5B	$6B	$6.9B	$8.9B	$16.4B	$17.6B	$17.8B	$18.6B
Instruments	-	$6.3B	$6.4B	$6.8B	$7.8B	$7.9B	$7.6B	$7.4B	$7.3B
Product revenues	$17.4B	-	-	-	-	-	-	-	-

Revenue by region

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
North America	-	$12.1B	$12.9B	$17.1B	$19.7B	$24.6B	$22.8B	$22.5B	$23B
Europe	-	$6.2B	$6.4B	$8.3B	$11.1B	$10.8B	$10.7B	$10.9B	$11.8B
Asia-Pacific	-	$5.3B	$5.5B	$5.8B	$7.2B	$8.1B	$7.9B	$8B	$8.1B
Other regions	-	$750M	$764M	$1B	$1.2B	$1.4B	$1.5B	$1.6B	$1.6B
United States	$10.1B	-	-	-	-	-	-	-	-
Other	$8.7B	-	-	-	-	-	-	-	-
China	$2.1B	-	-	-	-	-	-	-	-

Operating income by segment

Line	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Life Sciences Solutions	$1.9B	$2.2B	$2.4B	$6.1B	$7.8B	$5.6B	$3.4B	$3.5B	$3.8B
Laboratory Products and Biopharma Services	$1B	$1.3B	$1.3B	$1.3B	$1.8B	$2.9B	$3.4B	$3.1B	$3.4B
Analytical Instruments	$1B	$1.2B	$1.3B	$808M	$1.2B	$1.5B	$1.9B	$2B	$1.7B
Specialty Diagnostics	$927M	$952M	$930M	$1.4B	$1.3B	$1B	$1.1B	$1.2B	$1.3B

* derived: a fourth quarter as the year less the three filed quarters, or a remainder as the total less the parts. All other figures are as filed.

About this page

Every figure on this page is read from Thermo Fisher Scientific Inc.'s own SEC filings: the statement lines from the SEC's XBRL company-facts feed, the revenue splits from the segment and revenue notes of each 10-K and 10-Q. Nothing is typed in or estimated. The cache refreshes daily.

Read the Risk & Quality report on Thermo Fisher Scientific Inc. or see all companies.